The combination of Tamoxifen and growth factor receptor kinase inhibitor (RKI) is also one of the main therapeutic approaches for Tamoxifen‐resistant breast cancer with overexpression of EGFR or HER‐2. Here, ERBB2 is linked to breast cancer.